²úÆ·ÖÐÐÄ
Å£ËøÁ´ËØ(DES£©ELISA¼ì²âÊÔ¼ÁºÐ
Å£ÌÇ»¯µ°°×(GSP£©ELISA¼ì²âÊÔ¼ÁºÐ
Å£ÌìÃŶ¬°±Ëá°±»ù×ªÒÆÃ¸(AST£©ELISA¼ì²âÊÔ¼ÁºÐ
ţ͸Ã÷ÖÊËáø(HAase£©ELISA¼ì²âÊÔ¼ÁºÐ
Å£ÍÑÑõßÁषÓ;ÍÑÑõßÁà¤ßø(DPD£©ELISA¼ì²âÊÔ¼ÁºÐ
Å£ÍíÆÚÌÇ»ù»¯ÖÕÄ©²úÎï(AGEs£©ELISA¼ì²âÊÔ¼ÁºÐ
ţάÉúËØD½áºÏµ°°×(DBP£©ELISA¼ì²âÊÔ¼ÁºÐ
ţϸ°ûÉ«ËØP4502E1(CYP2E1£©ELISA¼ì²âÊÔ¼ÁºÐ
Å£Ðļ¡ÌØÒìÐÔ¼¡¸Æµ°°×T(cTnT£©ELISA¼ì²âÊÔ¼ÁºÐ
Å£Ó²Ö¬õ£¸¨Ã¸AÈ¥±¥ºÍø(SCD£©ELISA¼ì²âÊÔ¼ÁºÐ
Å£Ó²Ö¬õ£¸¨Ã¸AÈ¥±¥ºÍø1(SCD-1£©ELISA¼ì²âÊÔ¼ÁºÐ
Å£ÓÎÀëÖ¬·¾Ëá(FFA£©ELISA¼ì²âÊÔ¼ÁºÐ
Å£ÓÕµ¼ÐÍNOºÏø(iNOS£©ELISA¼ì²âÊÔ¼ÁºÐ
Å£ÔÏËάµ°°×-1(FBN1£©ELISA¼ì²âÊÔ¼ÁºÐ
Å£ÔÐͪ(PROG£©ELISA¼ì²âÊÔ¼ÁºÐ
Å£ÔØÖ¬µ°°×B100(apo-B100£©ELISA¼ì²âÊÔ¼ÁºÐ
Å£ÔØÖ¬µ°°×C2(apo-C2£©ELISA¼ì²âÊÔ¼ÁºÐ
Å£ÔØÖ¬µ°°×C3(apo-C3£©ELISA¼ì²âÊÔ¼ÁºÐ
Å£Õ³µ°°×1(MUC1£©ELISA¼ì²âÊÔ¼ÁºÐ
Å£µ¥´¿ðåÕ¶¾¿¹Ô1(HSV-Ag1£©ELISA¼ì²âÊÔ¼ÁºÐ
Ò³´Î7/15 ÿҳ20Ìõ ×ܹ²287Ìõ Ê×Ò³ÉÏÒ»Ò³ÏÂһҳβҳ
µÚ6Äê